Effect of Immunostimulatory CpG-Oligonucleotides in Chronic Lymphocytic Leukemia B Cells

References

• Tokunaga T., Yano O., Kuramoto E., Kimura Y., Yamamoto T., Katoaka T., Yamaoto S. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium, BCG I. Isolation, physicochemical characterization and antitumor activity. Journal of the National Cancer Institute 1984; 72: 955–962
   PubMed Web of Science ®Google Scholar
• Messina J. P., Gilkeson G. S., Pisetsky D S. Stimulation of in vitro murine lymphocyte proliferation by bacterial, DNA. Journal of Immunology 1991; 147: 1759–1764
   PubMed Web of Science ®Google Scholar
• Yamamoto S., Yamamoto T., Shimada S., Kuramato E., Yano O., Kataoka T., Tokunaga T. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiology and Immunology 1992; 36: 983–997
   PubMed Web of Science ®Google Scholar
• Krieg A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky D. A., Klinman D M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546–549
   PubMed Web of Science ®Google Scholar
• Pisetsky D S. Immune Activation by bacterial DNA: a new genetic code. Immunity 1996; 5: 303–310
   PubMed Web of Science ®Google Scholar
• Fearon D. T., Locksley R M. The instructive role of innate immunity in the aquired immune response. Science 1996; 272: 50–53
   PubMed Web of Science ®Google Scholar
• Anderson K V. Toll signaling pathways in the innate immune response. Current Opinion in Immunology 2000; 12: 13–19
   PubMed Web of Science ®Google Scholar
• Luke A., O'Neill J., Dinarello C A. The IL-1 receptor / toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol Today 2000; 21: 206–209
   PubMedGoogle Scholar
• Hacker H., Vabulas R. M., Takeuchi O., Hoshino K., Akira S., Wagner H. Immune cell activation by bacterial DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. Journal of Experimental Medicine 2000; 192: 595–600
   PubMed Web of Science ®Google Scholar
• Hacker H., Mischak H., Miethke T., Liptay S., Schmid Sparwasser R., Heeg T., Lipford G. B., Wagner H. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non specific endocytosis and endosomal maturation. Embo Journal 1998; 17: 6230–6240
   PubMed Web of Science ®Google Scholar
• Hartmann G., Krieg A M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. Journal of Immunology 2000; 164: 944–953
   PubMed Web of Science ®Google Scholar
• Hacker H., Mischak H., Hacker G., Eser S., Prenzel N., Ullrich A., Wagner H. Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells. Embo Journal 1999; 18: 6973–6982
   PubMed Web of Science ®Google Scholar
• Liang H., Reich C. F., Pisetsky D. S., Lipsky P. E. The role of cell surface receptors in the activation of human B cells by phosphorothioate oligonucleotides. Journal of Immunol 2000; 165: 1438–1445
   PubMed Web of Science ®Google Scholar
• Liang H., Nishioka Y., Reich C. F., Pisetsky D. S., Lipsky P. Activation of Human B cells by Phosphorothioate Oligonucleotides. Journal of Clinical Investigation 1996; 98: 1119–1129
   PubMed Web of Science ®Google Scholar
• Hartmann G., Krieg A M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. Journal of Immunology 2000; 164: 944–953
   PubMed Web of Science ®Google Scholar
• Lang R., Hultner L., Lipford G. B., Wagner H., Heeg K. Guanosine-rich oligonucleotides induce proliferation of macrophage progenitors in cultures of murine bone marrow cells. European Journal of Immunology 1999; 29: 3496–3506
   PubMed Web of Science ®Google Scholar
• Stacey K. J., Sweet M. J., Hume D A. Macrophages ingest and are activated by bacterial, DNA. Journal of Immunology 1996; 157: 2116–2122
   PubMed Web of Science ®Google Scholar
• Sparwasser T., Koch E. S., Vabulas R. M., Heeg K., Lipford G. B., Ellwart J. W., Wagner H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendiric cells. European Journal of Immunology 1998; 28: 2045–2054
   PubMed Web of Science ®Google Scholar
• Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol. 1999; 73: 329–368
   PubMed Web of Science ®Google Scholar
• Krieg A M. The role of CpG motifs in innate immunity. Current Opinion in Immunology 2000; 12: 35–43
   PubMed Web of Science ®Google Scholar
• Bauer M., Heeg K., Wagner H., Lipford G B. DNA activates human immune cells through a CpG sequence dependent manner. Immunology 1999; 97: 699–705
   PubMed Web of Science ®Google Scholar
• Decker Schneller T., Sparwasser F., Tretter T. T, Lipford G. B., Wagner H., Peschel C. Immunstimulatory CpG-Oligonucleotides cause proliferation, cytokine secretion and an immunogenic phenotype in B-CLL patients. Blood 2000; 95: 999–1006
   PubMed Web of Science ®Google Scholar
• Bancherau J., Steinman R M. Dendritic cells and the control of immunity. Nature 1998; 392: 245–252
   PubMed Web of Science ®Google Scholar
• Hartmann G. CpG DNA as a signal for growth, activation and maturation of human dendritic cells. Proceedings of the National Academy of Science of the United States of America 1999; 96: 9305–9310
   PubMed Web of Science ®Google Scholar
• Chu R. S., Targoni O. S., Krieg A. M., Lehmann P. V., Harding C V. CpG-Oligonucleotides act as adjuvants that switch on T Helper 1 immunity. Journal of Experimental Medicine 1997; 186: 1623–1631
   PubMed Web of Science ®Google Scholar
• Walker P. S., Scharton-Kersten T., Krieg A. M., Love-Homan L., Rowton E. D., Udey M. C., Vogel J C. Immunostimolatory oligonucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFN-γ dependent mechanisms. Proceedings of the National Academy of Science of the United States of America 1999; 96: 6970–6975
   PubMed Web of Science ®Google Scholar
• Bendigs S., Salzer U., Lipford G. B., Wagner H., Heeg K. CpG-oligonucleotides costimulate primary T cells in the absence of antigen presenting cells. European Journal of Immunology 1999
   PubMed Web of Science ®Google Scholar
• Iho S., Yamamoto T., Takahashi T., Yamamoto S. Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T cells to induce IFN-gamma production in vitro. Journal of Immunology 1999; 163: 3642–52
   PubMed Web of Science ®Google Scholar
• Lipford G. B., Sparwasser T., Zimmermann S., Heeg K., Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. Journal of Immunology 2000; 165: 1228–35
   PubMed Web of Science ®Google Scholar
• Sun S., Zhang X., Tough D. F., Sprent J. Type I Interferon-mediated stimulation of T cells by CpG DNA. Journal of Experimental Medicine 1998; 188: 2335–2442
   PubMed Web of Science ®Google Scholar
• Cowdery J. S., Chace J. H., Yi A. K., Krieg A M. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. Journal of Immunology 1996; 156: 4570–4575
   PubMed Web of Science ®Google Scholar
• Halpern M. D., Kurlander R. J., Pisetsky D S. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cellular Immunology 1996; 167: 72–78
   PubMed Web of Science ®Google Scholar
• Lipford G. B., Heeg K., Wagner H. Bacterial DNA as immune cell activator. Trends in Microbiology 1998; 6: 496
   PubMed Web of Science ®Google Scholar
• McCluskie M. J., Weeretna R. D., Davis H L. The role of CpG-DNA in vaccines. Springer Seminars in Immunopathology 2000; 22: 125–132
   PubMed Web of Science ®Google Scholar
• Sparwasser T., Miethke T., Lipford G. B., Borschert K., Hacker H., Heeg K., Wagner H. Bacterial DNA causes septic shock. Nature 1997; 386: 336–337
   PubMed Web of Science ®Google Scholar
• Segal B. M., Chanf J. T., Shevach E M. CpG oligonucleotides are potent adjuvants for the activation of auto-reactive encephalitogenic T cells in vivo. Journal of Immunology 2000; 164: 5683–5688
   PubMed Web of Science ®Google Scholar
• Segal B. M., Klinman D. M., Shevach E M. Microbial products induce autoimmune disease by an IL-12 dependent pathway. Journal of Immunology 1997; 158: 5087–5090
   PubMed Web of Science ®Google Scholar
• Lipford G. B., Bauer T., Zimmermann S., Koch E. S., Heeg K., Wagner H. Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines. European Journal of Immunology 1997; 27: 2340–2344
   PubMed Web of Science ®Google Scholar
• Fong L., Engelman E G. Dendritic cells in cancer immunotherapy. Annual Rev Immunol 2000; 18: 245–273
   PubMed Web of Science ®Google Scholar
• Forni G., Lollini P. L., Musiani P., Colombo M P. Immunoprevention of cancer: is the time ripe. Cancer Research 2000; 60: 2571–2575
   PubMed Web of Science ®Google Scholar
• Weiner G J. CpG DNA in cancer immunoterapy. Current Topics in Microbiology and Immunology 2000; 247: 157–170
   PubMed Web of Science ®Google Scholar
• Davila E., Celis E. Repeated administration of cytosine-phosphorothiolated gunanine-containing Oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. Journal of Imunology 2000; 165: 539–547
   PubMed Web of Science ®Google Scholar
• Vabulas R. M., Pircher H., Lipford G. B., Hacker H., Wagner H. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. Journal of Immunology 2000; 164: 2372–2378
   PubMed Web of Science ®Google Scholar
• Carpentier A. F., Chen L., Maltoni F., Delattre J Y. Oligonucleotides containing CpG motifs can induce rejection of neuroblastoma in mice. Cancer Research 1999; 59: 5429–5432
   PubMed Web of Science ®Google Scholar
• Weiner G. J., Liu H. M., Woolridge J. E., Dahle C. E., Krieg A M. Immunostimulatory Oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proceedings of the National Academy of Science of the United States of America 1997; 94: 10833–10837
   PubMed Web of Science ®Google Scholar
• Liu H. M., Newbrough S. E., Bhatia S. K., Dahle C. E., Krieg A. M., Weiner G J. Immunostimulatory CpG Oligonucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 1998; 92: 3730–3736
   PubMed Web of Science ®Google Scholar
• Woolridge J. E., Ballas Z., Krieg A. M., Weiner G J. Immunostimulatory Oligonucleotides containing CpG motifs enhance the efficiacy of monoclonal antibody therapy of lymphoma. Blood 1997; 89: 2994–2998
   PubMed Web of Science ®Google Scholar
• Glennie M. J., Johnson P W. Clinical trials of antibody therapy. Immunology Today 2000; 21: 403–410
   PubMedGoogle Scholar
• Lokhorst H. M., Liebowitz D. Adoptive T-cell therapy. Seminars in Hematology 1999; 36: 26–29
   PubMed Web of Science ®Google Scholar
• Egeter O., Mocikat R., Ghoreschi K., Dieckmann A., Rocken M. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from non-transgenic mice. Cancer Research 2000; 60: 1515–1520
   PubMed Web of Science ®Google Scholar
• O'Brien S., Del Giglio A., Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995; 85: 307–318
   PubMed Web of Science ®Google Scholar
• Wendtner C. M., Schmitt B., Wilhelm M., Dreger P., Montserrat E., Emmerich B., Hallek M. Redefining the therapeutic goals in chronic lymphocytic leukemia: towards an evidence-based, risk adapted therapy. Annals of Oncology 1999; 10: 505–509
   PubMed Web of Science ®Google Scholar
• Michallet M., Thiebaut A., Dreger P., Remes K., Milpied N., Santini G., Hamon M., Bjorkstrand B., Kimby E., Belhabri A., Tanguy M X, Appen J F. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcomittee on behalf of the EBMT Chronic Leukemias Working Party (CLWP). British Journal of Haematology 2000; 108: 595–601
   PubMed Web of Science ®Google Scholar
• Hainsworth J. D., Bums H. A., Morrissey L. H., Litchy S., Scullin D. C., Bearden J. D., Richards P., Greco F A. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95: 3052–3056
   PubMed Web of Science ®Google Scholar
• Osterborg A., Dyer M. J., Bunjes D., Pangalis G. A., Catovsky Y., Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 1997; 15: 1567–1574
   PubMed Web of Science ®Google Scholar
• Johnson T. A., Rassenti L. Z., Kipps T J. Ig VH1 genes expressed in B-cell chronic lymphocytic leukemia exhibit distinctive molecular features. Journal of Immunology 1997; 158: 235–246
   PubMed Web of Science ®Google Scholar
• Decker Flohr T., Trautmann T., Aman M. J., Holter W., Majdic O., Huber C., Peschel C. Role of accessory cells in cytokine production by T cells in Chronic B-cell lymphocytic leukemia. Blood 1995; 86: 1115–1123
   PubMed Web of Science ®Google Scholar
• Dazzi F., D'Andrea E., Biasi G., De Silvestro G., Gaidano G., Schena M., Tison T., Vianello F., Girolami A., Caligaris-Cappio F. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin. Immunol Immunopathol 1995; 75: 26–32
   PubMedGoogle Scholar
• Ranheim E. A., Kipps T J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. Journal of Experimental Medicine 1993; 177: 925–935
   PubMed Web of Science ®Google Scholar
• Buhmann R., Nolle A., Westhaus D., Emmerich B., Hallek M. CD40-activated B-Cell chronic lymphocytic leukemia cells for Tumor Immunotherapy: Stimulation of allogeneic versus autologous T cells generate different types of effector cells. Blood 1999; 93: 1992–2002
   PubMed Web of Science ®Google Scholar
• Kato K., Cantwell M. J., Sharma S., Kipps T J. Gene Transfer of CD40-Ligand Induces Autologous Immune Recognition of Chronic Lymphocytic Leukemia B Cells. Journal of Clinical Investigation 1998; 101: 1133–1141
   PubMed Web of Science ®Google Scholar
• Wierda G. W., Cantwel I M. J., Woods S. J., Rassenti L. Z., Prussak C. E., Kipps T J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917–2924
   PubMed Web of Science ®Google Scholar
• Hivroz C., Grillot-Courvallin C., Brouet J. C., Seligman M. Heterogeneity of responsiveness of chronic lymphocytic leukemic B cells to B cell growth factor IL-2. European Journal of Immunology 1986; 16: 1001–1004
   PubMed Web of Science ®Google Scholar
• Nelson B. H., Willerford D M. Biology of the Interleukin-2 Receptor. Advances in Immunology 1998; 70: 1–81
   PubMed Web of Science ®Google Scholar
• Decker Schneller T., Kronschnabl E., Dechow T., Lipford G. B., Wagner H., Peschel C. Immunostimulatory CpG-Oligonukleotides induce the expression of functional IL-2 receptors on B-CLL cells: Costimulation with IL-2 results in a highly immunogenic phenotype. Experimental Hematology 2000; 28: 558–568
   PubMed Web of Science ®Google Scholar
• Lenschow D. J., Walunas T. L., Bluestofne J A. CD28/B7 system of T cell costimulation. Annual Revue in Immunology 1996; 14: 233–258
   PubMed Web of Science ®Google Scholar
• Fiels P. E., Finch R. J., Gray G. S., Zollner R., Sturmhoefel K., Lee K., Wolf S., Gajewski T. F., Fitch F W. B7.1 is a quantitatively stronger costimulus than B7.2 in activation of naive TCR-transgenic T cells. Journal of 1998; 161: 5268–5275
   Google Scholar
• Ginaldi L., De Martinis M., Matutes E., Farahat N., Morilla R., Catovsky M. Levels of expression of CD19 and CD20 in chronic B cell leukemias. Journal of Clinical Pathology 1998; 51: 364–369
   PubMed Web of Science ®Google Scholar
• Ginaldi L., Martinis M., Matutes E., Farahat N., Morilla R., Dyer M., Catovsky D. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leukemia Research 1998; 22: 185–191
   PubMed Web of Science ®Google Scholar
• Reiter Y., Kreitman R. J., Brinkmann U., Pastan I. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated pseudomonas exotoxin. International Journal of Cancer 1994; 58: 142–149
   PubMed Web of Science ®Google Scholar
• Kreitman R. J., Wilson W. H., Robbins D., Margulies I., Stetler-Stevenson M., Waldmann T. A., Pastan I. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 2000; 10: 3340–3348
   Google Scholar
• Kreitman R. J., Wilson W. H., White J. D., Stetler-Stevenson M., Jaffe E. S., Giardina S., Waldmann T. A., Pastan I. Phase I Trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. Journal of Clinical Oncology 2000; 18: 1622–1636
   PubMed Web of Science ®Google Scholar
• Francisco J. A., Schreiber G. J., Comereski C. R., Mezza L. E., Warner G. L., Davidson T. J., Ledbetter J. A., Siegall C B. In vivo efficacy and toxicity of a single-chain immunotoxin targeted to CD40. Blood 1997; 89: 4493–500
   PubMed Web of Science ®Google Scholar
• Meinhardt G., Wendtner C. M., Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. Journal of Molecular Medicine 1999; 77: 282–293
   PubMed Web of Science ®Google Scholar
• Goodman M. G., Wormsley S. B., Spinosa J. C., Piro L D. Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle. Blood 1994; 84: 3457–3464
   PubMed Web of Science ®Google Scholar
• Qintanilla-Martinez L., Thieblemont C., Kumar F., Pinyol M., Campo E., Jaffe E. S., Raffeld M. Mantle cell lymphoma lack expression of p27kipl, a cyclin-dependent kinase inhibitor. American Journal of Pathology 1998; 153: 175–182
   PubMed Web of Science ®Google Scholar
• Shapiro G. I., Harper J W. Anticancer drug targets: Cell cycle checkpoint control. Journal of Clinical Investigation 1999; 104: 1645–1653
   PubMed Web of Science ®Google Scholar